Point-of-care Pharmacogenomic Testing to Optimize Isoniazid Dosing for Tuberculosis Prevention

Clinical trial NCT05413551 · COMPLETED

Trial details

NCT number: NCT05413551
Sponsor: Stanford University
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Tuberculosis Infection Isoniazid Adverse Reaction

Start date: 2023-03-23
Primary completion: 2025-04-23
Enrollment: 78

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.